Drug Profile
Research programme: hepatitis C virus NS5A inhibitors - Presidio Pharmaceuticals
Alternative Names: HCV NS5A inhibitors - Presidio Pharmaceuticals; PPI-1301; PPI-437; PPI-833; XTL-DOSLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator XTL Biopharmaceuticals
- Developer Presidio Pharmaceuticals
- Class Small molecules
- Mechanism of Action Hepatitis C virus NS 5 protein inhibitors; Hepatitis C virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Hepatitis C
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Hepatitis-C in USA (PO)
- 24 Feb 2012 Presidio Pharmaceuticals' hepatitis C virus NS5A inhibitors programme is available for licensing. http://www.presidiopharma.com/
- 26 May 2010 Presidio selects a second clinical candidate, PPI 1301, for evaluation in IND-enabling studies